全文获取类型
收费全文 | 228569篇 |
免费 | 17676篇 |
国内免费 | 7369篇 |
专业分类
耳鼻咽喉 | 1262篇 |
儿科学 | 7784篇 |
妇产科学 | 1820篇 |
基础医学 | 20030篇 |
口腔科学 | 3680篇 |
临床医学 | 24453篇 |
内科学 | 58325篇 |
皮肤病学 | 2759篇 |
神经病学 | 26437篇 |
特种医学 | 6618篇 |
外国民族医学 | 4篇 |
外科学 | 17548篇 |
综合类 | 30786篇 |
现状与发展 | 34篇 |
一般理论 | 9篇 |
预防医学 | 19263篇 |
眼科学 | 2406篇 |
药学 | 16208篇 |
196篇 | |
中国医学 | 10191篇 |
肿瘤学 | 3801篇 |
出版年
2024年 | 716篇 |
2023年 | 4834篇 |
2022年 | 8695篇 |
2021年 | 12295篇 |
2020年 | 11550篇 |
2019年 | 8839篇 |
2018年 | 8700篇 |
2017年 | 8485篇 |
2016年 | 8816篇 |
2015年 | 8499篇 |
2014年 | 16033篇 |
2013年 | 17733篇 |
2012年 | 13030篇 |
2011年 | 14171篇 |
2010年 | 11129篇 |
2009年 | 10704篇 |
2008年 | 10760篇 |
2007年 | 10414篇 |
2006年 | 9285篇 |
2005年 | 7642篇 |
2004年 | 6527篇 |
2003年 | 5602篇 |
2002年 | 4736篇 |
2001年 | 4115篇 |
2000年 | 3427篇 |
1999年 | 2931篇 |
1998年 | 2785篇 |
1997年 | 2487篇 |
1996年 | 2213篇 |
1995年 | 1997篇 |
1994年 | 1830篇 |
1993年 | 1562篇 |
1992年 | 1526篇 |
1991年 | 1336篇 |
1990年 | 1044篇 |
1989年 | 899篇 |
1988年 | 841篇 |
1987年 | 763篇 |
1986年 | 667篇 |
1985年 | 785篇 |
1984年 | 649篇 |
1983年 | 406篇 |
1982年 | 471篇 |
1981年 | 380篇 |
1980年 | 298篇 |
1979年 | 260篇 |
1978年 | 196篇 |
1977年 | 178篇 |
1976年 | 138篇 |
1975年 | 51篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
22.
23.
目的:探究替米沙坦对冠心病合并糖尿病肾病患者疗效的影响情况。方法:56例探究目标对象均为某院接收的冠心病合并糖尿病肾病患者,挑选时间2018年6月~2019年6月。将"计算机表法"作为分组的参考,分配为参照组(n=28例)执行依那普利治疗,探究组(n=28例)执行替米沙坦治疗。结果:探究组的LVEF、LVEDd、肌酐、24h尿蛋白4项指标与参照组相比,差异有统计学意义(P<0.05);收缩压、舒张压、空腹血糖、餐后2h血糖4项指标与参照组相比,差异没有统计学意义(P>0.05)。结论:冠心病合并糖尿病肾病患者选择替米沙坦治疗后,心室功能的重构以及肾脏预后结局均得到改善,且临床效果比依那普利好,值得借鉴。 相似文献
24.
Tian-Yuan Xiong Fang-Yang Huang Qi Liu Yong Peng Yuan-Ning Xu Jia-Fu Wei 《Annals of medicine》2020,52(7):361-366
Abstract
Background
Comorbidities are commonly seen in patients with coronavirus disease 2019 (COVID-19), but the clinical implication is not yet well-delineated. We aim to characterize the prevalence and clinical implications of comorbidities in patients with COVID-19. 相似文献25.
杨永磊 《长春中医药大学学报》2015,(4):749-750
目的 观察参麦注射液治疗冠心痛的临床效果.方法 选取我院2013年4月-2014年1月间收治的冠心病患者94例,依据治疗方案不同分为治疗组48例,对照组46例,2组患者入院均根据病情给予能量合剂、血管扩张剂、减轻心脏负荷药物,并进行对症、溶栓及抗心律失常等常规治疗,治疗组患者在常规治疗的基础上给予参麦注射液静滴治疗,1次/d,用药2周为1疗程;于治疗2疗程后观察治疗效果,并对比2组患者临床症状、心电图改善情况及红细胞超氧化物歧化酶(E-SOD)平均活性,血浆过氧化脂质(P-LPO)、红细胞过氧化脂质(E-LPO)含量变化.结果 治疗组治疗后总有效率显著高于对照组(P<0.05);治疗组胸闷、心悸、心绞痛及ST段下移、T渡低平或倒置患者改善率显著均高于对照组(P<0.05);治疗组治疗后E-SOD活性显著高于对照组,P-LPO、E-LPO含量显著低于对照组(P<0.05).结论 参麦注射液可有效缓解冠心病患者临床症状,降低血中脂质过氧化物浓度,缓解心肌缺血状态. 相似文献
26.
Kota Sahara Rin Yamada Takashi Fujiwara Koichi Koizumi Shin‐ichiro Horiguchi Tsunekazu Hishima Tatsuro Yamaguchi 《Digestive endoscopy》2015,27(7):768-771
Idiopathic myointimal hyperplasia of mesenteric veins (IMHMV) is a rare and poorly understood ischemic colitis that occurs in the rectosigmoid colon of predominantly young, previously healthy, male patients. A 76‐year‐old Japanese man presented to our hospital with a 1‐year history of worsening diarrhea, lower abdominal pain, and weight loss (−6 kg). Laboratory evaluation revealed white blood cell count of 13 200/μL, C‐reactive protein level of 2.0 mg/dL (normal range, 0.0–0.3), and negative results for stool culture (including Clostridium difficile). Colonoscopy showed circumferential and edematous narrowing of the sigmoid colon with deep longitude ulceration. Biopsy was done and examination of the specimen demonstrated no specific ischemia. The patient was treated with bowel rest, antibiotics, and i.v. fluids; however, his symptoms worsened. Finally, sigmoidectomy was carried out. Histological examination demonstrated significant myointimal hyperplasia of mesenteric veins leading to thickening and stenosis of the venous lumen. Therefore, the final diagnosis was IMHMV. Three months following sigmoidectomy, he was asymptomatic. 相似文献
27.
28.
29.
30.
Jennifer Wang Jonathan G. Stine Scott L. Cornella Curtis K. Argo Steven M. Cohn 《临床与转化肝病杂志(英文版)》2015,3(4):254-259
Background and Aims: Gastric antral vascular ectasia (GAVE) is commonly found in patients with cirrhosis, but it is also associated with other diseases in the absence of cirrhosis. Whether GAVE confers a different severity of gastrointestinal (GI) bleeding between patients with and without cirrhosis remains unknown. We aim to examine whether there is a difference in clinically significant GI bleeding due to GAVE in patients with or without cirrhosis. Methods: This is a retrospective case-control study of patients who were diagnosed with GAVE between January 2000 and June 2014. Patients were categorized into cirrhosis and noncirrhosis groups, and those with an additional GI bleeding source were excluded. Univariate comparisons and multivariable models were constructed using logistic regression. Results: In total, 110 patients diagnosed with GAVE on esophagogastroduodenoscopy (EGD) were included in our analysis; 84 patients had cirrhosis (76.4%) and 26 (23.6%) did not. Active GI bleeding was more prevalent in patients without cirrhosis (63.4% vs. 32.1%, p=0.003) despite similar indications for EGD, and endoscopic treatment with argon plasma coagulation (APC) was required more often in this group, approaching statistical significance (27% vs. 10.7%, p=0.056). There was no difference in bleeding severity, as evidenced by similar re-bleeding rates, surgery, or death attributed to uncontrolled bleeding. The strongest independent risk factor for GI bleeding was the absence of cirrhosis (odds ratio (OR): 5.151 (95% confidence interval (CI): 1.08-24.48, p=0.039). Conclusions: Patients with GAVE in the absence of cirrhosis are at higher risk for active GI bleeding and require more frequent endoscopic treatment than similar patients with cirrhosis. It may be worthwhile to treat GAVE in this population even in the absence of active bleeding. 相似文献